When it comes to biotech investing, the value opportunities in Australia attract many of the world's smartest investors. Amongst them,…
More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is…
For patients given less than five years to live after being diagnosed with myelofibrosis, there is a new flicker of…
This morning’s announcement may have surprised many investors following the Pharmaxis (ASX: PXS) story because where on earth does Parkinson’s…
Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX:…